CLINICAL_TRIALS
trial_result
· 2013-04-18
Clinical Trial Update: A Pharmacokinetic and Safety Study of Paliperidone Palmitate (JNS010) in Participants With Schizophrenia [Phase 2]
Summary
This Phase 2 study evaluates the pharmacokinetics and safety of paliperidone palmitate in participants with schizophrenia.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Janssen Pharmaceutical K.K. | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED | Results posted: 2013-04-18